drugset / Trial / NCT01662999

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

NCT01662999

Phase 1 Completed 42 enrolled AstraZeneca
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together

Timeline

Start
2012-08
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral